Chronic effects of triiodothyronine in combination with imipramine on 5-HT transporter, 5-HT1A and 5-HT2A receptors in adult rat brain

Neuropsychopharmacology

Volumn 24, Issue 6, 2001, Pages 652-662

  Moreau, X ^a   Jeanningros, R ^a   Mazzola Pomietto, P ^a  

^a INSERM   (France)

Author keywords

5 HT transporter; 5 HT1A receptor; 5 HT2A receptor; Brain; Tricyclic antidepressant; Triiodothyronine

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; CITALOPRAM; DESIPRAMINE; IMIPRAMINE; KETANSERIN; LIOTHYRONINE; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN TRANSPORTER; THYROID HORMONE; TRICYCLIC ANTIDEPRESSANT AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BRAIN CORTEX; BRAIN LEVEL; CONTROLLED STUDY; DEPRESSION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; HIPPOCAMPUS; LIOTHYRONINE BLOOD LEVEL; LONG TERM EXPOSURE; MALE; MESENCEPHALON; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR DENSITY; TREATMENT OUTCOME;

EID: 0035013379     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(00)00234-7     Document Type: Article

References (55)

1. Aronson R., Offman H.J., Joffe R.T., Naylor C.D. Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch Gen Psychiatry. 53:1996;842-848.
2. Barsano C.H., Garces J., Iqbal Z. Metabolic implications of low-dose triiodothyronine administration in rats. Relevance to the adjunctive use of triiodothyronine in the treatment of depression Biol Psychiatry. 35:1994;814-823.
3. Bel N., Artigas F. In vivo effects of the simultaneous blockade of serotonin and norepinephrine transporters on serotonergic function. Microdialysis studies. J Pharmacol Exp Ther. 278:1996;1064-1072.
4. Blier P., de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci. 15:1994;220-226.
5. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 72:1976;248-254.
6. Breese G.R., Traylor T.D., Prange A.J. The effect of triiodothyronine on the disposition and actions of imipramine. Psychopharmacologia. 25:1972;101-111.
7. 2 receptors and the abundancies of 5-HT receptor and transporter mRNA in the cortex, hippocampus and dorsal raphe of three strains of rat. Brain Res. 638:1994;311-324.
8. Chaput Y., de Montigny C., Blier P. Presynaptic and postsynaptic modifications of the serotonin system by long-term administration of antidepressant treatments. An in vivo electrophysiologic study in the rat. Neuropsychopharmacology. 5:1991;219-229.
9. 3H]5-HT uptake. effect of administration of various antidepressant treatments Neuropharmacology. 32:1993;737-743.
10. Coppen A., Whybrow P.C., Noguera R., Maggs R., Prange A.J. The comparative antidepressant value of L-tryptophan and imipramine with and without attempted potentiation by liothyronine. Arch Gen Psychiatry. 26:1972;234-241.
11. 3H]paroxetine binding in rat cortex. Psychiatry Res. 73:1997;173-179.
12. de Montigny C., Aghajanian G.K. Tricyclic antidepressants. Long-term treatment increases responsivity of rat forebrain neurons to serotonin Science. 202:1978;1303-1306.
13. 3H]paroxetine binding and serotonin content of rat brain. Absence of changes following antidepressant treatments Eur J Pharmacol. 235:1993;137-142.
14. 2A receptors. a review of in vivo studies Behav Brain Res. 73:1996;177-181.
15. Escobar-Morreale H.F., Escobar del Rey F., Obregon M.J., Morreale de Escobar G. Only the combined treatment with thyroxine and triiodothyronine ensures euthyroidism in all tissues of thyroidectomized rat. Endocrinology. 137:1996;2490-2502.
16. Feighner J.P., King L.J., Schuckit M.A., Croughan J., Briscoe W. Hormonal potentiation of imipramine and ECT in primary depression. Am J Psychiatry. 128:1972;1230-1238.
17. Gallager D.W., Bunney W.E. Jr. Failure of chronic lithium treatment to block tricyclic antidepressant-induced 5-HT supersensitivity. Naunyn Schmiedebergs Arch Pharmacol. 307:1979;129-133.
18. Garbutt J., Malepour B., Brunswick D., Jonnalagadda M.R., Jolliff L., Podolak R., Wilson I., Prange A.J. Effects of triiodothyronine on drug levels and cardiac function in depressed patients treated with imipramine. Am J Psychiatry. 136:1979;980-982.
19. 2 receptor-mediated head-twitch behaviour following antidepressant treatment to mice. Br J Pharmacol. 83:1984;235-242.
20. Gravel P., de Montigny C. Noradrenergic denervation prevents sensitization of rat forebrain neurons to serotonin by tricyclic antidepressant treatment. Synapse. 1:1987;233-239.
21. Gupta S., Masand P., Tanquary J.F. Thyroid hormone supplementation of fluoxetine in the treatment of major depression. Br J Psychiatry. 159:1991;866-867.
22. Gur E., Lerer B., Newman M.E. Chronic clomipramine and triiodothyronine increase serotonin levels in rat frontal cortex in vivo. Relationship to serotonin autoreceptor activity J Pharmacol Exp Ther. 288:1999;81-87.
23. Heninger G.R., Charney D.S. Mechanisms of action antidepressant treatment. Implications for the etiology and treatment of depressive disorders Meltzer H.Y. Psychopharmacology. The Third Generation of Progress:1987;535-544 Raven Press, New York.
24. Joffe R.T. Triiodothyronine potentiation of the antidepressant effect of phenelzine. J Clin Psychiatry. 49:1988;409-410.
25. Joffe R.T. Triiodothyronine potentiation of fluoxetine in depressed patients. Can J Psychiatry. 37:1992;48-50.
26. Joffe R.T., Singer W. A comparison of triiodothyronine and thyroxine in the potentiation of tricyclic antidepressants. Psychiatry Res. 32:1990;241-251.
27. Joffe R.T., Sokolov S.T. Thyroid hormones, the brain, and affective disorders. Crit Rev Neurobiol. 8:1994;45-63.
28. Joffe R.T., Sokolov S.T., Singer W. Thyroid hormone treatment of depression. Thyroid. 5:1995;235-239.
29. Kennedy J.A., Jarrett D.B., Wellby M.L. Influence of imipramine on the hypothalamic/pituitary/thyroid axis of the rat. Metabolism. 46:1997;1429-1434.
30. 2 receptors in the rat brain. J Psychiatry Neurosci. 19:1994;63-67.
31. Kovachich G.B., Aronson C.E., Brunswick D.J. Effect of repeated administration of antidepressants on serotonin uptake sites in limbic and neocortical structures of rat brain determined by quantitative autoradiography. Neuropsychopharmacology. 7:1992;317-324.
32. 2A receptors, 5-HT uptake sites and tryptophan hydroxylase activity in mature brain. Neuroendocrinology. 69:1999;453-459.
33. 2) and beta-adrenergic receptors in rat cerebral cortex following novel and classical antidepressant treatment. J Psychiatry Neurosci. 16:1991;209-214.
34. Lesch K.P., Aulakh C.S., Wolozin B.L., Tolliver T.J., Hill J.L., Murphy D.L. Regional brain expression of serotonin transporter mRNA and its regulation by reuptake inhibiting antidepressants. Mol Brain Res. 17:1993;31-35.
35. Maes M., Meltzer H.Y. The serotonin hypothesis of major depression. Bloom F.E., Kupfer D.J. Psychopharmacology. The Fourth Generation of Progress:1995;933-944 Raven Press, New York.
36. Maj J., Bijak M., Dziedzicka-Wasylewska M., Rogoz R., Rogoz Z., Skuza G., Tokarski T. The effects of paroxetine given repeatedly on the 5-HT receptor subpopulation in the rat brain. Psychopharmacology. 127:1996;73-82.
37. Munson P.J., Rodbard D. Ligand. A versatile computerized approach for characterization of ligand-binding systems Anal Biochem. 107:1980;220-239.
38. Nankai M., Yamada S., Toru M. Downregulation of serotonin uptake sites in rat brain induced by concomitant chronic administration of desipramine and repeated stress. Jpn J Psychiatry Neurol. 45:1991;105-106.
39. 2C receptors stably expressed in the human neuroblastoma cell line SH-SY5Y. J Neurochem. 69:1997;1031-1038.
40. Papp M., Klimek V., Willner P. Effects of imipramine on serotonergic and beta-adrenergic receptor binding in a realistic animal model of depression. Psychopharmacology. 114:1994;309-314.
41. 3H]spiroperidol by chronic treatment with the antidepressant amitriptyline. J Pharmacol Exp Ther. 215:1980;582-587.
42. Piñeyro G., Blier P., Dennis T., de Montigny C. Desensitization of the neuronal 5-HT carrier following its long-term blockade. J Neurosci. 14:1994;3036-3047.
43. Prange A.J., Wilson I.C., Rabon A.M., Lipton M.A. Enhancement of imipramine antidepressant activity by thyroid hormone. Am J Psychiatry. 126:1969;457-469.
44. 2 receptor mRNA levels. Eur J Pharmacol. 207:1991;169-172.
45. 2A receptors. molecular biology and mechanism of regulation Crit Rev Neurobiol. 12:1998;319-338.
46. Rudorfer M.V., Potter W.Z. Antidepressants. A comparative review of the clinical pharmacology and therapeutic use of the 'newer' versus the 'older' drugs. Drugs. 37:1989;713-738.
47. Sandrini M., Vitale G., Vergoni A.V., Ottani A., Bertolini A. Effect of acute and chronic treatment with triiodothyronine on serotonin levels and serotonergic receptor subtypes in the rat brain. Life Sci. 58:1996;1551-1559.
48. 2A receptor induces an antidepressant-like effect in mice. Mol Pharmacol. 52:1997;1056-1063.
49. Steiner M., Radwan M., Elizur A., Blum I., Atson A., Davidson S. Failure of L-triiodothyronine (T3) to potentiate tricyclic antidepressant response. Curr Ther Res. 23:1978;655-659.
50. 2 receptor sites and inositoltrisphosphate levels in rat brain. Neurochem Res. 22:1997;1095-1099.
51. Thomas D.R., Nelson D.R., Johnson A.M. Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology. 93:1987;193-200.
52. 2 receptors and transport sites for serotonin. Brain Res. 615:1993;87-94.
53. 1A receptors in rat brain following antidepressant drug treatment. Synapse. 4:1989;347-352.
54. Wheatley D. Potentiation of amitriptyline by thyroid hormone. Arch Gen Psychiatry. 26:1972;229-233.
55. Wilson I.C., Prange A.J., McClane T.K., Rabon A.M., Lipton M.A. Thyroid-hormone enhancement of imipramine in nonretarded depressions. N Engl J Med. 282:1970;1063-1067.